NCT06783816View on ClinicalTrials.gov

A Novel CAR-T Combined Expression of IL-15 in the Treatment of Malignant Hematological Tumors

NARecruitingINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

December 1, 2023

Primary Completion Date

June 1, 2028

Study Completion Date

June 1, 2028

Conditions
Acute Lymphocytic LeukemiaLymphoma,Non-HodgkinRelapsed Refractory Multiple Myeloma
Interventions
DRUG

chimeric antigen receptor gene modified T cells

The rate of intravenous infusion of CAR T cells was 10 mL to 20 mL/min, and the infusion was performed using a blood transfusion apparatus with a filter screen. Use saline rinsing tube prior to infusion; Rinse the infusion bag with 10 mL\~30 mL normal saline.

Trial Locations (1)

030000

RECRUITING

Shanxi Bethune Hospital, Taiyuan

All Listed Sponsors
lead

Shanxi Bethune Hospital

OTHER